Cargando…
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Ovarian cancer is the second leading cause of death from gynecologic malignancies worldwide. Management of platinum-resistant disease is challenging and clinical outcomes with standard chemotherapy are poor. Over the past decades, significant efforts have been made to understand drug resistance and...
Autores principales: | Gonzalez-Ochoa, Eduardo, Veneziani, Ana C, Oza, Amit M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387675/ https://www.ncbi.nlm.nih.gov/pubmed/37528890 http://dx.doi.org/10.1177/11795549231187264 |
Ejemplares similares
-
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
por: Matulonis, Ursula A., et al.
Publicado: (2023) -
Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers
por: Cui, Yingshu, et al.
Publicado: (2023) -
Sevoflurane augmentation in treatment-resistant depression: a clinical case study
por: Wang, Shikai, et al.
Publicado: (2020) -
Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression
por: Gómez-Revuelta, Marcos, et al.
Publicado: (2020) -
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models()
por: Ponte, Jose F., et al.
Publicado: (2016)